Literature DB >> 19556994

Integrating albuminuria and GFR in the assessment of diabetic nephropathy.

George Jerums1, Sianna Panagiotopoulos, Erosha Premaratne, Richard J MacIsaac.   

Abstract

The evaluation of diabetic nephropathy from research and clinical viewpoints depends on the assessment of two continuous variables, albumin excretion rate (AER) and glomerular filtration rate (GFR). These two parameters form the basis of both the European classification of five stages of diabetic nephropathy, assessed according to changes in AER and GFR (hyperfiltration, normoalbuminuria, microalbuminuria, macroalbuminuria and end-stage renal disease), and the National Kidney Foundation classification of five stages of chronic kidney disease based on categories of estimated GFR. Although increases in AER generally precede a decline in GFR, some patients follow a non-albuminuric pathway to renal impairment. In addition, studies indicate that GFR decreases in a linear fashion from normal or above-normal levels. Whether hyperfiltration is part of the pathogenetic process leading to diabetic nephropathy remains unclear. Ideally, both AER and GFR should be assessed at an early stage in patients being evaluated for diabetic nephropathy. New methods such as the use of cystatin-C-based equations for estimating GFR should be considered because current creatinine-based estimates are inaccurate at normal or high GFRs. Serial assessments of both AER and GFR might allow diabetic nephropathy to be diagnosed at early stages of the disease process that are selectively responsive to new interventions. The successful integration of AER categories with the recently defined stages of GFR represents a new challenge in the management of diabetic nephropathy.

Entities:  

Mesh:

Year:  2009        PMID: 19556994     DOI: 10.1038/nrneph.2009.91

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  90 in total

Review 1.  Albuminuric and non-albuminuric pathways to renal impairment in diabetes.

Authors:  R J Macisaac; G Jerums
Journal:  Minerva Endocrinol       Date:  2005-09       Impact factor: 2.184

2.  Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients.

Authors:  Wing Yee So; Alice P S Kong; Ronald C W Ma; Risa Ozaki; Cheuk Chun Szeto; Norman N Chan; Vanessa Ng; Chung Shun Ho; Christopher W K Lam; Chun Chung Chow; Clive S Cockram; Juliana C N Chan; Peter C Y Tong
Journal:  Diabetes Care       Date:  2006-09       Impact factor: 19.112

Review 3.  Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.

Authors:  C E Mogensen; E Vestbo; P L Poulsen; C Christiansen; E M Damsgaard; H Eiskjaer; A Frøland; K W Hansen; S Nielsen; M M Pedersen
Journal:  Diabetes Care       Date:  1995-04       Impact factor: 19.112

4.  Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.

Authors:  W A Wilmer; L A Hebert; E J Lewis; R D Rohde; F Whittier; D Cattran; A S Levey; J B Lewis; S Spitalewitz; S Blumenthal; R P Bain
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

5.  Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa study.

Authors:  Takashi Yamada; Mitsuhisa Komatsu; Ichiro Komiya; Yasuhiro Miyahara; Yukino Shima; Mitsuko Matsuzaki; Yuka Ishikawa; Reiko Mita; Mika Fujiwara; Nobuko Furusato; Kazue Nishi; Toru Aizawa
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

6.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 7.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

8.  Similar risks of nephropathy in patients with type I or type II diabetes mellitus.

Authors:  C Hasslacher; E Ritz; P Wahl; C Michael
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

9.  Predicting diabetic nephropathy in insulin-dependent patients.

Authors:  C E Mogensen; C K Christensen
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

10.  Nonalbuminuric renal insufficiency in type 2 diabetes.

Authors:  Richard J MacIsaac; Con Tsalamandris; Sianna Panagiotopoulos; Trudy J Smith; Karen J McNeil; George Jerums
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

View more
  37 in total

1.  Dynamic evaluation of renal resistive index in normoalbuminuric patients with newly diagnosed hypertension or type 2 diabetes.

Authors:  R M Bruno; E Daghini; L Landini; D Versari; A Salvati; E Santini; I Di Paco; A Magagna; S Taddei; L Ghiadoni; A Solini
Journal:  Diabetologia       Date:  2011-04-16       Impact factor: 10.122

2.  Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice.

Authors:  Tangli Xiao; Xu Guan; Ling Nie; Song Wang; Lei Sun; Ting He; Yunjian Huang; Jingbo Zhang; Ke Yang; Junping Wang; Jinghong Zhao
Journal:  Mol Cell Biochem       Date:  2014-05-22       Impact factor: 3.396

3.  Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus.

Authors:  Ligia Petrica; Adrian Vlad; Gheorghe Gluhovschi; Alina Zamfir; Cristina Popescu; Florica Gadalean; Victor Dumitrascu; Daliborca Vlad; Roxana Popescu; Silvia Velciov; Cristina Gluhovschi; Flaviu Bob; Oana Milas; Sorin Ursoniu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Associations between structural and functional changes to the kidney in diabetic humans and mice.

Authors:  David W Powell; David N Kenagy; Shirong Zheng; Susan C Coventry; Jianxiang Xu; Lu Cai; Edward C Carlson; Paul N Epstein
Journal:  Life Sci       Date:  2013-06-22       Impact factor: 5.037

5.  Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease.

Authors:  Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2010-10-19       Impact factor: 5.782

Review 6.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

7.  Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.

Authors:  Mark E Molitch; Michael Steffes; Wanjie Sun; Brandy Rutledge; Patricia Cleary; Ian H de Boer; Bernard Zinman; John Lachin
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 19.112

8.  High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.

Authors:  Linda H Ficociello; Elizabeth T Rosolowsky; Monika A Niewczas; Nicholas J Maselli; Janice M Weinberg; Ann Aschengrau; John H Eckfeldt; Robert C Stanton; Andrzej T Galecki; Alessandro Doria; James H Warram; Andrzej S Krolewski
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

9.  Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.

Authors:  Wen-Hao Tang; Fu-Huang Lin; Chien-Hsing Lee; Feng-Chih Kuo; Chang-Hsun Hsieh; Fone-Ching Hsiao; Yi-Jen Hung
Journal:  Endocrine       Date:  2013-06-18       Impact factor: 3.633

Review 10.  CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.

Authors:  Roberto Bassi; Alessia Fornoni; Alessandro Doria; Paolo Fiorina
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.